Search for: "Astellas Pharma US, Inc." Results 21 - 40 of 42
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
3 Sep 2014, 4:01 pm
This is the question which the IPKat posed last Friday, on learning that Case C-661/13 Astellas Pharma Inc. v Polpharma SA Pharmaceutical Works, a reference to the Court of Justice of the European Union (CJEU) of some questions relating to the so-called Bolar exemption, which spares some sorts of use of someone else's patent for experimental purposes from being a patent infringement. [read post]
20 Jul 2011, 4:04 am by Marie Louise
Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet. [read post]
29 Aug 2014, 7:30 am
Readers may still be looking forward to a ruling from the Court of Justice of the European Union (CJEU) in Case C-661/13 Astellas Pharma Inc. v Polpharma SA Pharmaceutical Works, which was excitedly publicised by this Kat here and here on account of its potential for clarifying the scope of Bolar exemptions from patent infringement in favour of experimental use. [read post]
22 Oct 2021, 2:10 pm by Tom Lamb
As stated in our initial article about serious Padcev skin reactions last month, we are investigating cases of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in patients using Padcev as possible drug injury lawsuits to be filed against Astellas Pharma US, Inc., the manufacturer of Padcev. [read post]
7 Sep 2012, 1:38 pm
Daniels, 42, of North Naples, a pharmaceutical representative, and his employer, Astellas Pharma U.S. [read post]
15 Jan 2014, 7:38 am
Pharmaceutical Works and Japanese company Astellas Pharma Inc; if you must know, the patent is for novel quinuclidine derivatives and pharmaceutical preparations. [read post]
12 Jul 2016, 7:22 am by Law Offices of Jeffrey S. Glassman
Both defendants in the case have since been purchased by other firms – OSI by Japanese company Astellas Pharma and Genetech by Swiss firm Hoffman-La Roche AG. [read post]
24 Jun 2014, 6:58 am by Duets Guest Blogger
However, I have never resorted to choosing random letters out of a hat…which is the only explanation I can come up with for why Astellas Pharma US, Inc. chose this name. [read post]
8 Nov 2007, 9:00 pm
You can separately subscribe to the IP Thinktank Global week in Review at [duncanbucknell.com]GlobalIP Think Tank top five's: (IP Think Tank),More on IP law in the virtual world: (VirtualLaw), Interesting times for the Citi brand: (IAM), Velcro has won control of the domain name velcro.biz: (OUT-LAW), The Economic Value of Patent 'Trolls': (IP Think Tank),Industry Trilateral group and the 'global patent application' project: (PatentDocs), Update on the BitTorrent war -… [read post]
31 May 2018, 4:26 pm by Kevin LaCroix
  Background Astellas Pharma U.S. is a pharmaceutical company and the U.S-based subsidiary of Astellas Pharma, Inc. [read post]
10 Jun 2011, 6:22 am by Bexis
Astellas Pharma, US, Inc., 2007 WL 2137782 (E.D. [read post]
14 May 2023, 7:07 pm
Reporting on recent investigation of Bain & Co.'s Shanghai offices, the rad on the Beijing offices of Mintz Group, cyber reviews of Micron Technology, Inc., and the detention of a Japanese employee of Astellas Pharma, Inc., suggests a broader purpose.Business executives who have consulted with Chinese authorities said the government aims to limit the information collected by foreign companies such as auditors, management consultants, and law firms that… [read post]
25 Jul 2008, 7:04 am
, (Daily Dose of IP), 26 August: WIPO symposium on IP and multilateral agreements – Geneva: (IPKat), 11-12 September: US LSI: 4th annual conference on ‘Current issues in complex IP licensing’ – Philadelphia: (Patent Docs), 11 September/15 October: PLI seminar on developments in pharmaceutical and biotech patent law – New York/San Francisco: (Patent Docs), 15-16 September: UniForum & SAIIPL domain name ADR workshop –… [read post]
1 Dec 2007, 9:00 am
: (Trademark Blog), Short paper on domain name monetization: (Trademark Blog),Comcast puts non-lawyer in charge of IP Strategy: (IAM),Are green technology IP rights owners about to become the new big pharma? [read post]
21 Sep 2021, 1:25 pm by Tom Lamb
Our law firm is investigating cases for patients who have suffered the Padcev skin side effects Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) as possible drug injury lawsuits to be filed against Astellas Pharma US, Inc., the manufacturer of Padcev. [read post]
18 May 2009, 5:24 am
: Omnicare, Inc v OHIM, Astellas Pharma GmbH (Class 46) CFI delivers judgment in case concerning ability of designer who assigns business and related IP to another company, to object when the company tries to register his name as a CTM: Elio Fiorucci v OHIM (IPKat) CFI: Good faith irrelevant when selling non-misleading sausages: Alberto Severi, in his own name and representing Cavazzuti e figli SpA, now known as Grandi Salumifici Italiani SpA v Regione Emilia-Romagna… [read post]